<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01610037</url>
  </required_header>
  <id_info>
    <org_study_id>CQVA149A2339</org_study_id>
    <secondary_id>2012-002057-38</secondary_id>
    <nct_id>NCT01610037</nct_id>
  </id_info>
  <brief_title>Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation</brief_title>
  <official_title>A Placebo and Active Controlled Study to Assess the Long-term Safety of Once Daily QVA149 for 52 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate to Severe Airflow Limitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the long-term safety of the fixed combination product QVA149 versus
      placebo and a standard of care treatment (tiotropium) in Chronic Obstructive Pulmonary
      Disease (COPD) patients with moderate to severe airflow limitation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Serious Adverse Events</measure>
    <time_frame>Week 52</time_frame>
    <description>The overall rate of serious adverse events reported from initiation through 30 days post last dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Composite Endpoint of All-cause Mortality, and Serious Cardio- and Cerebrovascular (CCV) Events.</measure>
    <time_frame>52 weeks</time_frame>
    <description>The endpoint of all-cause mortality and serious CCV events (composite) was chosen to further characterize any discernible risks. The patients with an event in the analysis were those who had at least one of the 2 events namely, all-cause mortality and serious CCV, during treatment or within 30 days after the date of last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-hoc Analysis: Percentage of Patients With Composite Endpoint of Cardiovascular Death and MACE</measure>
    <time_frame>52 weeks</time_frame>
    <description>The composite endpoint included all deaths and all serious CCV events, including MACE and events which were not considered MACE. A rigorous post hoc analysis was done on composite endpoint of CV deaths and major adverse cardiovascular events (MACE). The patients with an event in the analysis were those who had at least one of the 2 events namely, CV deaths and MACE, during treatment or within 30 days after the date of last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pre-Dose Forced Expiratory Volume Over in Second (FEV1)</measure>
    <time_frame>Day 22, 43, 85, 183, 274 and 364</time_frame>
    <description>Pulmonary function assessments were performed using centralized spirometry according to international standards. Baseline FEV1 was defined as the average of the pre-dose FEV1 measured at -45 minutes (min) and -15 min at day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Status as Measured by St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C)</measure>
    <time_frame>Measurment at day 364</time_frame>
    <description>The SGRQ-C contains 40 items divided into two parts covering three aspects of health related to COPD: Part I covers &quot;Symptoms&quot; and is concerned with respiratory symptoms, their frequency and severity; Part II covers &quot;Activity&quot; and is concerned with activities that cause or are limited by breathlessness; Part II is also concerned with &quot;Impacts&quot; which covers a range of aspects concerned with social functioning and psychological disturbances resulting from airways disease. A score will be calculated for each of these three subscales and a &quot;Total&quot; score will also be calculated. In each case the lowest possible value is zero and the highest 100. Higher values correspond to greater impairment of health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily, Morning and Evening Symptom Scores</measure>
    <time_frame>52 weeks</time_frame>
    <description>Patients will be provided with an electronic diary (eDiary) to record daily clinical symptoms, or rescue medication. The patients will be instructed to routinely complete the patient diary twice daily. There are 9 total symptom questions for a total possible score of 27 at each timepoint. A higher score means the patient is reporting more symptoms related to Chronic Obstructive Pulmonary Disease. The mean daily total symptom score, the mean daytime total symptom score and the mean nighttime total symptom score were calculated for each patient over 52 weeks. Diary data recorded during the 14 day run-in period were used to calculate the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Nights With 'no Nighttime Awakenings</measure>
    <time_frame>52 weeks</time_frame>
    <description>A night with 'no nighttime awakenings' is defined from diary data as any night where the patient did not wake up due to symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of no Daytime Symptoms</measure>
    <time_frame>52 weeks</time_frame>
    <description>A day with 'no daytime symptoms' is defined from the diary data as any day where the patient has recorded in the evening no cough, no wheeze, no production of sputum and no feeling of breathlessness (other than when running) during the past 12 hours (approx. 8 am to 8 pm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Days Able to Perform Usual Daily Activities.</measure>
    <time_frame>52 weeks</time_frame>
    <description>A day able to perform usual daily activities' is defined from diary data as any day where the patient was not prevented from performing their usual daily activities due to respiratory symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 1 Hour Post-dose Forced Vital Capacity (FVC) Measurements</measure>
    <time_frame>Day 1, 22, 43, 85, 183, 274 and 364</time_frame>
    <description>Pulmonary function assessments were performed using centralized spirometry according to international standards</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Premature Discontinuation</measure>
    <time_frame>Time varied from 5 - 407 days</time_frame>
    <description>Time to premature treatment discontinuation for each treatment group was displayed using a Kaplan-Meier curve. The date of last dose of study medication was considered as the event date and also as the censoring date for those patients who did not discontinue treatment early. The range of the 'time to treatment discontinuation' varied from 5-407 days in the Tiotropium group. Hence the model estimated lower limit of the median time to treatment discontinuation is greater than the scheduled treatment period of 52 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 1 Hour Post-dose FEV1 Measurements</measure>
    <time_frame>Day 1, 22, 43, 85, 183, 274 and 364</time_frame>
    <description>The avg 60 min post dose forced expiratory volume in 1 second (FEV1) at visit 4, 5, 6, 7, 8 and 9 will be analyzed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1215</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>QVA149</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QVA149</intervention_name>
    <description>QVA149 110/50 µg will be supplied as capsules in blister packs for once daily inhalation using the Novartis Concept1 SDDPI</description>
    <arm_group_label>QVA149</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Tiotropium 18 µg will be supplied as capsules in blister packs for once daily inhalation using the HandiHaler SDDPI</description>
    <arm_group_label>Tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo to QVA149A and Tiotropium will be supplied in the appropriate capsule in blister packs for use in either the Novartis Concept1 SDDPI or the HandiHaler SDDPI</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male and female adults aged ≥40 years.

          -  Patients with stable COPD according to GOLD strategy (GOLD 2011).

          -  Patients with airflow limitation indicated by a post-bronchodilator FEV1 ≥ 30% and
             &lt;80% of the predicted normal, and a post-bronchodilator.

          -  FEV1/FVC &lt; 0.70.

          -  Current or ex-smokers who have a smoking history of at least 10 pack years.

          -  Patients with an mMRC ≥ grade 2

        Exclusion criteria:

          -  History of long QT syndrome or prolonged QTc.

          -  Patients who have had a COPD exacerbation that required treatment with antibiotics
             and/or systemic corticosteroids and/or hospitalization in the 6 weeks prior to Visit
             1.

          -  Patients with Type I or uncontrolled Type II diabetes.

          -  Patients with a history of asthma or have concomitant pulmonary disease.

          -  Patients with paroxysmal (e.g. intermittent) atrial fibrillation. Only patients with
             persistent atrial fibrillation and controlled with a rate control strategy for at
             least six months could be eligible.

          -  Patients who have clinically significant renal, cardiovascular, neurological,
             endocrine, immunological, psychiatric, gastrointestinal, hepatic, or hematological
             abnormalities which could interfere with the assessment of safety.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>1028</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1113AAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1122AAK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1180AAX</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1425AUA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Florencio Varela</city>
        <state>Buenos Aires</state>
        <zip>B2705XAE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Florida</city>
        <state>Buenos Aires</state>
        <zip>B1602DQD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lanus</city>
        <state>Buenos Aires</state>
        <zip>B8000XAV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <zip>B1878FNR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Isidro</city>
        <state>Buenos Aires</state>
        <zip>B1642DCD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vicente Lopez</city>
        <state>Buenos Aires</state>
        <zip>B1638AAI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Concepcion del Uruguay</city>
        <state>Entre Rios</state>
        <zip>E3260EPD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <state>Rosario</state>
        <zip>S2000DBS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000AII</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000CXH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1842DID</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Corrientes</city>
        <zip>W3400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500CBA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salta</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000FIL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Armenia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sisak</city>
        <zip>44000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13619</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <state>HUN</state>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cegled</city>
        <zip>2700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Csorna</city>
        <zip>H-9300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erd</city>
        <zip>H-2030</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Godollo</city>
        <zip>2100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monor</city>
        <zip>2200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mosonmagyarovar</city>
        <zip>9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siofok</city>
        <zip>8600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szarvas</city>
        <zip>5540</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>A.p.</state>
        <zip>500 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Panjim</city>
        <state>Goa</state>
        <zip>403 002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mysore</city>
        <state>Karnataka</state>
        <zip>570004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trivandrum</city>
        <state>Kerala</state>
        <zip>695 011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bikaner</city>
        <state>Rajasthan</state>
        <zip>334 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302 039</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302023</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641 045.</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur - Maharashtra</city>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucheon-Si</city>
        <state>Gyeonggi-Do</state>
        <zip>14584</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>130-709</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daegu</city>
        <zip>705-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Incheon</city>
        <zip>403-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>León</city>
        <state>Guanajuato</state>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pachuca</city>
        <state>Hidalgo</state>
        <zip>42090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Panama City</city>
        <state>Panamá</state>
        <zip>0834-00363</zip>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Panama City</city>
        <state>Panamá</state>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-159</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115280</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>125315</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>N.Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St.-Petersburg</city>
        <zip>193231</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Knez Selo</city>
        <zip>18204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Golnik</city>
        <zip>4204</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kartal</city>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mersin</city>
        <zip>33079</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pendik / Istanbul</city>
        <zip>1330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yenisehir/Izmir</city>
        <zip>35110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leamington Spa</city>
        <state>Warwickshire</state>
        <zip>CV32 4RA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bradford</city>
        <state>West Yorkshire</state>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cheshire</city>
        <zip>CW1 4QJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Doncaster</city>
        <zip>DN2 5LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Merseyside</city>
        <zip>CH49 5PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newport</city>
        <zip>P030 5TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO6 3AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Estonia</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovenia</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Dominican Republic</country>
    <country>Former Serbia and Montenegro</country>
    <country>Guatemala</country>
    <country>Ireland</country>
    <country>Lithuania</country>
  </removed_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>May 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2012</study_first_posted>
  <results_first_submitted>February 1, 2016</results_first_submitted>
  <results_first_submitted_qc>May 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 15, 2016</results_first_posted>
  <last_update_submitted>May 9, 2016</last_update_submitted>
  <last_update_submitted_qc>May 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic obstructive pulmonary disease</keyword>
  <keyword>COPD</keyword>
  <keyword>QVA149</keyword>
  <keyword>QAB149</keyword>
  <keyword>NVA237</keyword>
  <keyword>Indacaterol maleate</keyword>
  <keyword>Glycopyronnium bromide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 2064 patients were screened, of whom 1216 patients were randomized to QVA149 110/50 µg o.d., tiotropium 18 µg o.d., or placebo. Of the 1216, one patient was randomized but not treated.</recruitment_details>
      <pre_assignment_details>One patient of the 1216 was randomized but did not receive treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>QVA149</title>
          <description>110/50 µg capsules for inhalation, o.d</description>
        </group>
        <group group_id="P2">
          <title>Tiotropium</title>
          <description>18 μg capsules for inhalation, o.d</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>To match QVA149 capsules for inhalation, o.d To match tiotropium capsules for inhalation, o.d</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>All Patients</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="407"/>
                <participants group_id="P2" count="405"/>
                <participants group_id="P3" count="404"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized Set (RAN)</title>
              <participants_list>
                <participants group_id="P1" count="407"/>
                <participants group_id="P2" count="405"/>
                <participants group_id="P3" count="404"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="407"/>
                <participants group_id="P2" count="405"/>
                <participants group_id="P3" count="403"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="348"/>
                <participants group_id="P2" count="354"/>
                <participants group_id="P3" count="320"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="84"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment and Follow up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="407"/>
                <participants group_id="P2" count="405"/>
                <participants group_id="P3" count="404"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="382"/>
                <participants group_id="P2" count="377"/>
                <participants group_id="P3" count="378"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The RAN included all randomized patients regardless of whether or not they actually received study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>QVA149</title>
          <description>110/50 µg capsules for inhalation, o.d</description>
        </group>
        <group group_id="B2">
          <title>Tiotropium</title>
          <description>18 μg capsules for inhalation, o.d</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>To match QVA149 capsules for inhalation, o.d To match tiotropium capsules for inhalation, o.d</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="407"/>
            <count group_id="B2" value="405"/>
            <count group_id="B3" value="404"/>
            <count group_id="B4" value="1216"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="7.89"/>
                    <measurement group_id="B2" value="64.1" spread="8.57"/>
                    <measurement group_id="B3" value="64.9" spread="7.95"/>
                    <measurement group_id="B4" value="64.5" spread="8.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="288"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="310"/>
                    <measurement group_id="B4" value="898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Serious Adverse Events</title>
        <description>The overall rate of serious adverse events reported from initiation through 30 days post last dose.</description>
        <time_frame>Week 52</time_frame>
        <population>The safety set included all patients who received at least one dose of study drug and had at least one post-baseline safety assessment. Patients were analyzed according to treatment received. A patient who had no adverse events also constitutes a safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>110/50 µg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium 18 µg o.d</title>
            <description>18 μg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>To match QVA149 capsules for inhalation, o.d To match tiotropium capsules for inhalation, o.d</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious Adverse Events</title>
          <description>The overall rate of serious adverse events reported from initiation through 30 days post last dose.</description>
          <population>The safety set included all patients who received at least one dose of study drug and had at least one post-baseline safety assessment. Patients were analyzed according to treatment received. A patient who had no adverse events also constitutes a safety assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="403"/>
                <count group_id="O3" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Composite Endpoint of All-cause Mortality, and Serious Cardio- and Cerebrovascular (CCV) Events.</title>
        <description>The endpoint of all-cause mortality and serious CCV events (composite) was chosen to further characterize any discernible risks. The patients with an event in the analysis were those who had at least one of the 2 events namely, all-cause mortality and serious CCV, during treatment or within 30 days after the date of last dose of study drug.</description>
        <time_frame>52 weeks</time_frame>
        <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>110/50 µg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium 18 µg o.d</title>
            <description>18 μg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>To match QVA149 capsules for inhalation, o.d To match tiotropium capsules for inhalation, o.d</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Composite Endpoint of All-cause Mortality, and Serious Cardio- and Cerebrovascular (CCV) Events.</title>
          <description>The endpoint of all-cause mortality and serious CCV events (composite) was chosen to further characterize any discernible risks. The patients with an event in the analysis were those who had at least one of the 2 events namely, all-cause mortality and serious CCV, during treatment or within 30 days after the date of last dose of study drug.</description>
          <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="405"/>
                <count group_id="O3" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-hoc Analysis: Percentage of Patients With Composite Endpoint of Cardiovascular Death and MACE</title>
        <description>The composite endpoint included all deaths and all serious CCV events, including MACE and events which were not considered MACE. A rigorous post hoc analysis was done on composite endpoint of CV deaths and major adverse cardiovascular events (MACE). The patients with an event in the analysis were those who had at least one of the 2 events namely, CV deaths and MACE, during treatment or within 30 days after the date of last dose of study drug.</description>
        <time_frame>52 weeks</time_frame>
        <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>110/50 µg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium 18 µg o.d</title>
            <description>18 μg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>To match QVA149 capsules for inhalation, o.d To match tiotropium capsules for inhalation, o.d</description>
          </group>
        </group_list>
        <measure>
          <title>Post-hoc Analysis: Percentage of Patients With Composite Endpoint of Cardiovascular Death and MACE</title>
          <description>The composite endpoint included all deaths and all serious CCV events, including MACE and events which were not considered MACE. A rigorous post hoc analysis was done on composite endpoint of CV deaths and major adverse cardiovascular events (MACE). The patients with an event in the analysis were those who had at least one of the 2 events namely, CV deaths and MACE, during treatment or within 30 days after the date of last dose of study drug.</description>
          <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="405"/>
                <count group_id="O3" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pre-Dose Forced Expiratory Volume Over in Second (FEV1)</title>
        <description>Pulmonary function assessments were performed using centralized spirometry according to international standards. Baseline FEV1 was defined as the average of the pre-dose FEV1 measured at -45 minutes (min) and -15 min at day 1.</description>
        <time_frame>Day 22, 43, 85, 183, 274 and 364</time_frame>
        <population>The full analysis set (FAS) included all randomized patients who eceived at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>110/50 µg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium 18 µg o.d</title>
            <description>18 μg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>To match QVA149 capsules for inhalation, o.d To match tiotropium capsules for inhalation, o.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pre-Dose Forced Expiratory Volume Over in Second (FEV1)</title>
          <description>Pulmonary function assessments were performed using centralized spirometry according to international standards. Baseline FEV1 was defined as the average of the pre-dose FEV1 measured at -45 minutes (min) and -15 min at day 1.</description>
          <population>The full analysis set (FAS) included all randomized patients who eceived at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="405"/>
                <count group_id="O3" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22 (n=378, 383, 361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1733" spread="0.18537"/>
                    <measurement group_id="O2" value="0.1018" spread="0.18389"/>
                    <measurement group_id="O3" value="-0.0148" spread="0.16758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (n=380, 375, 345)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1751" spread="0.20800"/>
                    <measurement group_id="O2" value="0.0961" spread="0.18261"/>
                    <measurement group_id="O3" value="-0.0196" spread="0.18178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (n=373, 373, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1752" spread="0.20198"/>
                    <measurement group_id="O2" value="0.0785" spread="0.19606"/>
                    <measurement group_id="O3" value="-0.0506" spread="0.19369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183 (n=356, 358, 314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1557" spread="0.21754"/>
                    <measurement group_id="O2" value="0.0714" spread="0.20358"/>
                    <measurement group_id="O3" value="-0.0583" spread="0.20305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 274 (n=343, 351, 303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1463" spread="0.21424"/>
                    <measurement group_id="O2" value="0.0750" spread="0.21489"/>
                    <measurement group_id="O3" value="-0.0601" spread="0.20936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 364 (n=333, 346, 297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1468" spread="0.22933"/>
                    <measurement group_id="O2" value="0.0559" spread="0.22433"/>
                    <measurement group_id="O3" value="-0.0826" spread="0.21443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Status as Measured by St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C)</title>
        <description>The SGRQ-C contains 40 items divided into two parts covering three aspects of health related to COPD: Part I covers &quot;Symptoms&quot; and is concerned with respiratory symptoms, their frequency and severity; Part II covers &quot;Activity&quot; and is concerned with activities that cause or are limited by breathlessness; Part II is also concerned with &quot;Impacts&quot; which covers a range of aspects concerned with social functioning and psychological disturbances resulting from airways disease. A score will be calculated for each of these three subscales and a &quot;Total&quot; score will also be calculated. In each case the lowest possible value is zero and the highest 100. Higher values correspond to greater impairment of health status.</description>
        <time_frame>Measurment at day 364</time_frame>
        <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>110/50 µg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium 18 µg o.d</title>
            <description>18 μg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>To match QVA149 capsules for inhalation, o.d To match tiotropium capsules for inhalation, o.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Status as Measured by St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C)</title>
          <description>The SGRQ-C contains 40 items divided into two parts covering three aspects of health related to COPD: Part I covers &quot;Symptoms&quot; and is concerned with respiratory symptoms, their frequency and severity; Part II covers &quot;Activity&quot; and is concerned with activities that cause or are limited by breathlessness; Part II is also concerned with &quot;Impacts&quot; which covers a range of aspects concerned with social functioning and psychological disturbances resulting from airways disease. A score will be calculated for each of these three subscales and a &quot;Total&quot; score will also be calculated. In each case the lowest possible value is zero and the highest 100. Higher values correspond to greater impairment of health status.</description>
          <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="343"/>
                <count group_id="O2" value="349"/>
                <count group_id="O3" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.79" spread="12.611"/>
                    <measurement group_id="O2" value="-6.12" spread="13.695"/>
                    <measurement group_id="O3" value="-2.18" spread="13.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily, Morning and Evening Symptom Scores</title>
        <description>Patients will be provided with an electronic diary (eDiary) to record daily clinical symptoms, or rescue medication. The patients will be instructed to routinely complete the patient diary twice daily. There are 9 total symptom questions for a total possible score of 27 at each timepoint. A higher score means the patient is reporting more symptoms related to Chronic Obstructive Pulmonary Disease. The mean daily total symptom score, the mean daytime total symptom score and the mean nighttime total symptom score were calculated for each patient over 52 weeks. Diary data recorded during the 14 day run-in period were used to calculate the baseline.</description>
        <time_frame>52 weeks</time_frame>
        <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>110/50 µg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium 18 µg o.d</title>
            <description>18 μg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>To match QVA149 capsules for inhalation, o.d To match tiotropium capsules for inhalation, o.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily, Morning and Evening Symptom Scores</title>
          <description>Patients will be provided with an electronic diary (eDiary) to record daily clinical symptoms, or rescue medication. The patients will be instructed to routinely complete the patient diary twice daily. There are 9 total symptom questions for a total possible score of 27 at each timepoint. A higher score means the patient is reporting more symptoms related to Chronic Obstructive Pulmonary Disease. The mean daily total symptom score, the mean daytime total symptom score and the mean nighttime total symptom score were calculated for each patient over 52 weeks. Diary data recorded during the 14 day run-in period were used to calculate the baseline.</description>
          <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="405"/>
                <count group_id="O3" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Daily total symptom score (n=395, 395, 385)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3478" spread="1.91692"/>
                    <measurement group_id="O2" value="-1.2283" spread="1.93241"/>
                    <measurement group_id="O3" value="-0.7683" spread="1.73598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daytime total symptom score (n= 380, 385, 374)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1688" spread="1.93350"/>
                    <measurement group_id="O2" value="-1.0669" spread="1.90366"/>
                    <measurement group_id="O3" value="-0.5641" spread="1.62577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nighttime total symptom score (n= 387, 388, 375)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9731" spread="1.96898"/>
                    <measurement group_id="O2" value="-0.9532" spread="1.78168"/>
                    <measurement group_id="O3" value="-0.5984" spread="1.73356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Nights With ‘no Nighttime Awakenings</title>
        <description>A night with ‘no nighttime awakenings’ is defined from diary data as any night where the patient did not wake up due to symptoms.</description>
        <time_frame>52 weeks</time_frame>
        <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>110/50 µg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium 18 µg o.d</title>
            <description>18 μg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>To match QVA149 capsules for inhalation, o.d To match tiotropium capsules for inhalation, o.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Nights With ‘no Nighttime Awakenings</title>
          <description>A night with ‘no nighttime awakenings’ is defined from diary data as any night where the patient did not wake up due to symptoms.</description>
          <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum</population>
          <units>Percentage of nights</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="388"/>
                <count group_id="O3" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.34" spread="30.115"/>
                    <measurement group_id="O2" value="10.66" spread="26.579"/>
                    <measurement group_id="O3" value="8.21" spread="28.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of no Daytime Symptoms</title>
        <description>A day with ‘no daytime symptoms’ is defined from the diary data as any day where the patient has recorded in the evening no cough, no wheeze, no production of sputum and no feeling of breathlessness (other than when running) during the past 12 hours (approx. 8 am to 8 pm).</description>
        <time_frame>52 weeks</time_frame>
        <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>110/50 µg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium 18 µg o.d</title>
            <description>18 μg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>To match QVA149 capsules for inhalation, o.d To match tiotropium capsules for inhalation, o.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of no Daytime Symptoms</title>
          <description>A day with ‘no daytime symptoms’ is defined from the diary data as any day where the patient has recorded in the evening no cough, no wheeze, no production of sputum and no feeling of breathlessness (other than when running) during the past 12 hours (approx. 8 am to 8 pm).</description>
          <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum</population>
          <units>Percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="380"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="374"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.56" spread="19.670"/>
                    <measurement group_id="O2" value="4.72" spread="15.942"/>
                    <measurement group_id="O3" value="1.78" spread="15.733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Days Able to Perform Usual Daily Activities.</title>
        <description>A day able to perform usual daily activities’ is defined from diary data as any day where the patient was not prevented from performing their usual daily activities due to respiratory symptoms.</description>
        <time_frame>52 weeks</time_frame>
        <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>110/50 µg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium 18 µg o.d</title>
            <description>18 μg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>To match QVA149 capsules for inhalation, o.d To match tiotropium capsules for inhalation, o.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Days Able to Perform Usual Daily Activities.</title>
          <description>A day able to perform usual daily activities’ is defined from diary data as any day where the patient was not prevented from performing their usual daily activities due to respiratory symptoms.</description>
          <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum</population>
          <units>Percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="380"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="374"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.79" spread="31.006"/>
                    <measurement group_id="O2" value="6.54" spread="30.215"/>
                    <measurement group_id="O3" value="1.13" spread="25.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 1 Hour Post-dose Forced Vital Capacity (FVC) Measurements</title>
        <description>Pulmonary function assessments were performed using centralized spirometry according to international standards</description>
        <time_frame>Day 1, 22, 43, 85, 183, 274 and 364</time_frame>
        <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>110/50 µg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium 18 µg o.d</title>
            <description>18 μg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>To match QVA149 capsules for inhalation, o.d To match tiotropium capsules for inhalation, o.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 1 Hour Post-dose Forced Vital Capacity (FVC) Measurements</title>
          <description>Pulmonary function assessments were performed using centralized spirometry according to international standards</description>
          <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="405"/>
                <count group_id="O3" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1(n=403, 402, 399)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3331" spread="0.30312"/>
                    <measurement group_id="O2" value="0.2806" spread="0.28293"/>
                    <measurement group_id="O3" value="0.0630" spread="0.22884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (n=384, 381, 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3971" spread="0.40009"/>
                    <measurement group_id="O2" value="0.3123" spread="0.36755"/>
                    <measurement group_id="O3" value="0.0178" spread="0.33624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (n=380, 373, 351)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4021" spread="0.42797"/>
                    <measurement group_id="O2" value="0.2966" spread="0.37124"/>
                    <measurement group_id="O3" value="0.0274" spread="0.35681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (376, 371, 345)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4169" spread="0.42175"/>
                    <measurement group_id="O2" value="0.2867" spread="0.40131"/>
                    <measurement group_id="O3" value="0.0035" spread="0.36897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183 (n=364, 359, 317)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3880" spread="0.45342"/>
                    <measurement group_id="O2" value="0.2822" spread="0.39781"/>
                    <measurement group_id="O3" value="-0.0283" spread="0.36919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 274 (n=349, 352, 306)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3582" spread="0.43072"/>
                    <measurement group_id="O2" value="0.2821" spread="0.40546"/>
                    <measurement group_id="O3" value="-0.0404" spread="0.37777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 364 (n= 336, 347, 302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3153" spread="0.46560"/>
                    <measurement group_id="O2" value="0.2224" spread="0.40778"/>
                    <measurement group_id="O3" value="-0.0498" spread="0.39908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Premature Discontinuation</title>
        <description>Time to premature treatment discontinuation for each treatment group was displayed using a Kaplan-Meier curve. The date of last dose of study medication was considered as the event date and also as the censoring date for those patients who did not discontinue treatment early. The range of the ‘time to treatment discontinuation’ varied from 5-407 days in the Tiotropium group. Hence the model estimated lower limit of the median time to treatment discontinuation is greater than the scheduled treatment period of 52 weeks.</description>
        <time_frame>Time varied from 5 - 407 days</time_frame>
        <population>The Safety set consisted of all patients that received at least one dose of study medication and had at least one post-baseline safety assessment. Patients were analyzed according to treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>110/50 µg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium 18 µg o.d</title>
            <description>18 μg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>To match QVA149 capsules for inhalation, o.d To match tiotropium capsules for inhalation, o.d</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Premature Discontinuation</title>
          <description>Time to premature treatment discontinuation for each treatment group was displayed using a Kaplan-Meier curve. The date of last dose of study medication was considered as the event date and also as the censoring date for those patients who did not discontinue treatment early. The range of the ‘time to treatment discontinuation’ varied from 5-407 days in the Tiotropium group. Hence the model estimated lower limit of the median time to treatment discontinuation is greater than the scheduled treatment period of 52 weeks.</description>
          <population>The Safety set consisted of all patients that received at least one dose of study medication and had at least one post-baseline safety assessment. Patients were analyzed according to treatment received.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="405"/>
                <count group_id="O3" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">NA - insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="378">NA - insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="NA">NA - insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 1 Hour Post-dose FEV1 Measurements</title>
        <description>The avg 60 min post dose forced expiratory volume in 1 second (FEV1) at visit 4, 5, 6, 7, 8 and 9 will be analyzed.</description>
        <time_frame>Day 1, 22, 43, 85, 183, 274 and 364</time_frame>
        <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>110/50 µg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium 18 µg o.d</title>
            <description>18 μg capsules for inhalation, o.d</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>To match QVA149 capsules for inhalation, o.d To match tiotropium capsules for inhalation, o.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 1 Hour Post-dose FEV1 Measurements</title>
          <description>The avg 60 min post dose forced expiratory volume in 1 second (FEV1) at visit 4, 5, 6, 7, 8 and 9 will be analyzed.</description>
          <population>The full analysis set (FAS) included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they were assigned to at randomization. If the patient was assigned to the wrong stratum for randomization, the patient was analyzed according to the actual (rather than assigned) stratum</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="405"/>
                <count group_id="O3" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=403, 402, 399)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2064" spread="0.14248"/>
                    <measurement group_id="O2" value="0.1567" spread="0.13349"/>
                    <measurement group_id="O3" value="0.0281" spread="0.11123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (n=384, 381, 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2883" spread="0.21074"/>
                    <measurement group_id="O2" value="0.2077" spread="0.20027"/>
                    <measurement group_id="O3" value="1.5827" spread="15.69990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (n=380, 373, 351)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2904" spread="0.23377"/>
                    <measurement group_id="O2" value="0.2008" spread="0.20752"/>
                    <measurement group_id="O3" value="1.6209" spread="16.89209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (n=376, 371, 345)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3026" spread="0.23260"/>
                    <measurement group_id="O2" value="0.1913" spread="0.23274"/>
                    <measurement group_id="O3" value="-0.0217" spread="0.20195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183 (n=364, 359, 317)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2860" spread="0.24351"/>
                    <measurement group_id="O2" value="0.1842" spread="0.22851"/>
                    <measurement group_id="O3" value="-0.0253" spread="0.21129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 274 (n=349, 352, 306)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2749" spread="0.24314"/>
                    <measurement group_id="O2" value="0.1681" spread="0.23626"/>
                    <measurement group_id="O3" value="-0.0360" spread="0.21854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 364 (n= 336, 347, 302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2619" spread="0.25967"/>
                    <measurement group_id="O2" value="0.1621" spread="0.23922"/>
                    <measurement group_id="O3" value="-0.0533" spread="0.21560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>QVA 149</title>
          <description>110/50 µg capsules for inhalation, o.d</description>
        </group>
        <group group_id="E2">
          <title>Tiotropium</title>
          <description>18 μg capsules for inhalation, o.d</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>To match QVA149 capsules for inhalation, o.d To match tiotropium capsules for inhalation, o.d</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Mesenteric artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pancreatitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Hepatic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Traumatic haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Adenolipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Malignant mediastinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Radiculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>VIth nerve paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Bronchial disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Jugular vein distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="294" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="294" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="309" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="269" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="274" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="287" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="405"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

